Anti-IgE [EPC]

40566 reported adverse events

Drugs of this class: OMALIZUMAB

These side effects are most commonly reported by patients taking drugs of the Anti-IgE [EPC] class:

# Side effect Count
0 ASTHMA 6918
1 DYSPNOEA 5492
2 URTICARIA 4131
3 COUGH 3674
4 DRUG INEFFECTIVE 3416
5 FATIGUE 3334
6 MALAISE 3305
7 HEADACHE 3002
8 WHEEZING 2777
9 PRURITUS 2707
See all common reactions for Anti-IgE [EPC]

Drugs of the Anti-IgE [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 TOTAL LUNG CAPACITY INCREASED 50 0.6329
1 FORCED EXPIRATORY FLOW DECREASED 34 0.6182
2 SMOKE SENSITIVITY 97 0.5988
3 FORCED EXPIRATORY VOLUME DECREASED 1079 0.5932
4 CHRONIC SPONTANEOUS URTICARIA 159 0.5032
5 PERFUME SENSITIVITY 135 0.4945
6 URTICARIA THERMAL 31 0.4697
7 BLOOD IMMUNOGLOBULIN E DECREASED 39 0.4382
8 EXPOSURE TO ALLERGEN 34 0.4304
9 DUST ALLERGY 124 0.4120
See all enriched reactions for Anti-IgE [EPC]